Drawing for YGX

USPTO serial 99105786

YGX

Reviewed by CopyMark Law Group

Status 688Notice of Allowance
Filing date
Status date
Registration date
—
Examiner
KONSCHAK, CARL A
Law office
INTENT TO USE SECTION

What this means

The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.

Status 688: Status 688 means a Notice of Allowance was issued. For intent-to-use applications, you must file a Statement of Use with specimens or request an extension before the deadline — usually six months from the notice date.

Need help with YGX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $549*

Plus Government fees of $600

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Eryn Y. Truong

Eryn Y. Truong LOZA & LOZA, LLP305 N. Second Ave., #127Upland, CA 91786United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of oncological, hematological, immunological, neurological, cardiovascular, metabolic, infectious, inflammatory, dermatological, gastrointestinal, hepatic, respiratory, renal, ophthalmic, and musculoskeletal diseases and disorders in humans; Veterinary pharmaceutical preparations for the treatment of oncological, hematological, immunological, neurological, cardiovascular, metabolic, infectious, inflammatory, dermatological, gastrointestinal, hepatic, respiratory, renal, ophthalmic, and musculoskeletal diseases and disorders in animalsACTIVE—
042Pharmaceutical research services; Pharmaceutical product evaluation; Research in the field of pharmaceuticals; Research relating to pharmaceuticals; Pharmaceutical research and development services; Research on the subject of pharmaceuticals; Laboratory research services relating to pharmaceuticals; Research and development of new products for the pharmaceutical industry; Consultancy in the field of pharmaceutical research; Consultancy relating to pharmaceutical research and development; Laboratory research in the field of pharmaceuticals; Technical research in the field of pharmaceuticals; Research and development in the pharmaceutical and biotechnology fields; Providing scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical products development; Pharmaceutical drug development services; Development of pharmaceutical preparations and medicines; Consultancy in the field of biotechnology; Consultancy relating to biotechnology; Biotechnology testing; Biotechnology research; Research relating to biotechnology; Scientific research; Scientific testing services in the field of pharmaceuticals; Scientific research services; Scientific research consulting; Scientific laboratory servicesACTIVE—
044Medical services in the nature of pharmaceutical consultation; Pharmaceutical advice; Pharmaceutical advisory services; Provision of pharmaceutical information, namely, providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticalsACTIVE—
045Intellectual property consultation; Intellectual property consultancy; Intellectual property licensing services; Management of intellectual property; Licensing of intellectual property; Licensing of intellectual property rights; Consultancy relating to intellectual property management; Intellectual property management services; Advisory services relating to intellectual property rights; Consultancy relating to the licensing of intellectual property; Intellectual property consultancy services for universities and research institutionsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 21, 2026EPPATEAS POST PUBLICATION AMENDMENT RECEIVED—
Apr 21, 2026NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Feb 24, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 24, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 18, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 29, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 23, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 23, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 23, 2026ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Nov 4, 2025GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Nov 4, 2025GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Nov 4, 2025CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Oct 31, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 31, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 31, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 26, 2025GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 26, 2025GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 26, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 26, 2025DOCKASSIGNED TO EXAMINER—
Jul 11, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 26, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Mar 26, 2025NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance